The clinical performance is complex and often involves multi-systemic burden. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment programs. Treatment and management of PML with low ADC require individualized development, usually including multidimensional management, including drug therapy, rehabilitation interventions, and regular follow-up visits. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many formerly difficult-to-treat neurological disorders have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions and timely adjusted according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of PML with low ADC. The platform serves a team of internationally authoritative experts at home and abroad in the field of neural systems related to the China International Medical Service System, providing the following services to patients: 1.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.